A COMPARISON OF THE SAFETY OF OLANZAPINE AND HALOPERIDOL IN COMBINATION WITH BENZODIAZEPINES IN EMERGENCY DEPARTMENT PATIENTS WITH ACUTE AGITATION

被引:20
|
作者
Wilson, Michael P. [1 ]
MacDonald, Kai [2 ]
Vilke, Gary M. [1 ]
Feifel, David [2 ]
机构
[1] UCSD Med Ctr, Dept Emergency Med, San Diego, CA 92103 USA
[2] UCSD Med Ctr, Dept Psychiat, San Diego, CA 92103 USA
来源
JOURNAL OF EMERGENCY MEDICINE | 2012年 / 43卷 / 05期
关键词
psychiatric emergencies; olanzapine; benzodiazepine; haloperidol; DOUBLE-BLIND; INTRAMUSCULAR OLANZAPINE; PSYCHOTIC AGITATION; MEDICINE RESEARCH; TRIAL; SCHIZOPHRENIA; MIDAZOLAM; DROPERIDOL;
D O I
10.1016/j.jemermed.2011.01.024
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Pharmacologic management of the agitated emergency department patient is controversial. The combination of olanzapine + benzodiazepines is not recommended by the manufacturer, but a recent report suggested harm only if the patient was intoxicated. Whether this is also true for haloperidol + benzodiazepines is not known. Objectives: The measurement of vital signs and ethanol levels in patients who received haloperidol with or without benzodiazepines was compared to a previous analysis of patients who received olanzapine with or without benzodiazepines. Methods: This is a structured retrospective chart review of patients who received parenteral haloperidol or parental olanzapine either with or without benzodiazepines. Results: There were 96 patients (71 haloperidol, 25 olanzapine) who met inclusion criteria. No patient in the olanzapine + benzodiazepine group had hypotension, although one patient in the olanzapine-only group did (6.7%); 2 patients in the haloperidol + benzodiazepines group (5.1%) and 2 patients in the haloperidol-only group (6.3%) had hypotension. In alcohol-negative (ETOH-) patients, neither olanzapine alone nor olanzapine + benzodiazepines was associated with decreased oxygen saturations. In ETOH+ patients, olanzapine alone was not associated with decreased oxygen saturations, but olanzapine + benzodiazepines were associated with lower oxygen saturations than haloperidol + benzodiazepines. Conclusions: In this sample, olanzapine alone or with a benzodiazepine was not associated with more hypotension than haloperidol. However, olanzapine + benzodiazepines were associated with lower oxygen saturations than haloperidol + benzodiazepines in ETOH+ but not ETOH- patients. In patients with known alcohol ingestion, haloperidol, haloperidol + benzodiazepines, or olanzapine alone may be better choices for treatment of agitation. (C) 2012 Elsevier Inc.
引用
收藏
页码:790 / 797
页数:8
相关论文
共 50 条
  • [21] A Double-Blind, Randomized Comparison Study of Efficacy and Safety of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia and Acute Agitated Behavior
    Chan, Hung-Yu
    Ree, Shao-Chun
    Su, Lien-Wen
    Chen, Jiann-Jyh
    Chou, Sun-Yuan
    Chen, Chih-Ken
    Chen, Ying-Sheue
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (03) : 355 - 358
  • [22] Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia
    Fang, Maosheng
    Chen, Honghui
    Li, Le-hua
    Wu, Renrong
    Li, Yi
    Liu, Lianzhong
    Ye, Meng
    Huang, Jizhong
    Zhu, Suoyu
    Wang, Gang
    Zhang, Qinge
    Zheng, Hongbo
    Zhang, Lulu
    Wang, Bo
    Zhou, Jianchu
    Zhao, Jing-Ping
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2012, 27 (02) : 107 - 113
  • [23] A Prospective Study of Intramuscular Droperidol or Olanzapine for Acute Agitation in the Emergency Department: A Natural Experiment Owing to Drug Shortages
    Cole, Jon B.
    Stang, Jamie L.
    DeVries, Paige A.
    Martel, Marc L.
    Miner, James R.
    Driver, Brian E.
    ANNALS OF EMERGENCY MEDICINE, 2021, 78 (02) : 274 - 286
  • [24] Comparison of Haloperidol Alone and in Combination with Midazolam for the Treatment of Acute Agitation in an Inpatient Palliative Care Service
    Ferraz Goncalves, Jose Antonio
    Almeida, Ana
    Costa, Isabel
    Silva, Paula
    Carneiro, Rui
    JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2016, 30 (04) : 284 - 288
  • [25] Managing Acute Agitation and Psychotic Symptoms in the Emergency Department
    Moukaddam, Nidal
    Choi, Raymond
    Tucci, Veronica
    ADOLESCENT PSYCHIATRY, 2019, 9 (02) : 118 - 128
  • [26] Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial
    Huang, Charles Lung-Cheng
    Hwang, Tzung-Jeng
    Chen, Yi-Hsing
    Huang, Guan-Hua
    Hsieh, Ming H.
    Chen, Hsiu-Hsi
    Hwu, Hai-Gwo
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2015, 114 (05) : 438 - 445
  • [27] A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients
    MacDonald, Kai
    Wilson, Michael P.
    Minassian, Arpi
    Vilke, Gary M.
    Perez, Rachel
    Cobb, Patrice
    Tallian, Kimberly
    Becker, Olga
    Feifel, David
    GENERAL HOSPITAL PSYCHIATRY, 2010, 32 (04) : 443 - 445
  • [28] Comparing Intubation Rates in Patients Receiving Parenteral Olanzapine With and Without a Parenteral Benzodiazepine in the Emergency Department
    Cole, Jon B.
    Stang, Jamie L.
    Collins, Jacob D.
    Klein, Lauren R.
    Devries, Paige A.
    Smith, Jennifer
    Pepin, Lesley C.
    Fuchs, Ryan T.
    Driver, Brian E.
    ANNALS OF EMERGENCY MEDICINE, 2024, 84 (06) : 658 - 667
  • [29] A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy
    Wright, P
    Meehan, K
    Birkett, M
    Lindborg, SR
    Taylor, CC
    Morris, P
    Breier, A
    CLINICAL THERAPEUTICS, 2003, 25 (05) : 1420 - 1428
  • [30] Safety and efficacy of pharmacologic agents used for rapid tranquilization of emergency department patients with acute agitation or excited delirium
    Kim, Hong K.
    Leonard, James B.
    Corwell, Brian N.
    Connors, Nicholas J.
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (02) : 123 - 138